Healthcare & Life Sciences.
Global Dealmakers.
Healthcare & Life Sciences.
Global Dealmakers.
Sage is attending BioEurope 2026
9-11 November in Cologne and would be pleased to meet you!
Specialist advice in licensing, partnering and M&A.
Turning life science innovation into opportunity
Sage helps biotechnology, pharmaceutical, regenerative medicine and health technology companies secure licensing partners, complete strategic M&A and unlock asset value worldwide. Our senior advisers combine deep sector expertise, global relationships and SAGEIQ-enabled market intelligence to identify the right counterparties and guide transactions from strategy to completion.
Turning life science innovation into opportunity
Sage helps biotechnology, pharmaceutical, regenerative medicine and health technology companies secure licensing partners, complete strategic M&A and unlock asset value worldwide. Our senior advisers combine deep sector expertise, global relationships and SAGEIQ-enabled market intelligence to identify the right counterparties and guide transactions from strategy to completion.
Who we work with
Biotech, MedTech, Regenerative Medicine and Diagnostics companies — licensing, development partnerships and strategic exits. Pharmaceutical and strategic buyers — focused sourcing of innovation and M&A opportunities. Investors and owners — structured partnering and sale processes to realise value.
Who we work with
Biotech, MedTech, Regenerative Medicine and Diagnostics companies — licensing, development partnerships and strategic exits. Pharmaceutical and strategic buyers — focused sourcing of innovation and M&A opportunities. Investors and owners — structured partnering and sale processes to realise value.
Why choose Sage
More than 30 years of life sciences experience, an international network and senior deal leadership from strategy through closing. SAGEIQ-enabled marketing intelligence helps us identify and prioritise relevant partners with precision, while our advisers shape the transaction and manage the process.
Why choose Sage
More than 30 years of life sciences experience, an international network and senior deal leadership from strategy through closing. SAGEIQ-enabled marketing intelligence helps us identify and prioritise relevant partners with precision, while our advisers shape the transaction and manage the process.
Selected transaction experience
Recent work includes advising PolyPid on its US and Canadian partnership with Azurity Pharmaceuticals for D-PLEX100, Hatchtech on the acquisition of Xeglyze by Pelthos Therapeutics, and Fabre-Kramer on its partnering agreement with Aytu BioPharma for EXXUA.
See the latest Sage news below for transaction announcements and explore About Sage for our platform, process and international expertise.
0+
0+
Businesses Advised
0+
0+
Businesses Advised
0+
0+
Transactions Advised
0+
0+
Transactions Advised
0+
0+
Years Experience
0+
0+
Years Experience
$0BN
$0BN
Cumulative Value
$0BN
$0BN
Cumulative Value
Sectors of expertise
We support pharmaceutical, biotechnology, regenerative medicine, medtech and diagnostics companies, alongside venture capital, private equity and strategic investors.
Therapeutic areas
Oncology, neuroscience, immunology and inflammation, regenerative medicine, rare diseases and infectious diseases
Modalities
Small molecules, biologics, cell and gene therapies, drug delivery, digital biomarkers, devices and AI-driven drug discovery.
Therapeutic areas
Oncology, neuroscience, immunology and inflammation, regenerative medicine, rare diseases and infectious diseases
Modalities
Small molecules, biologics, cell and gene therapies, drug delivery, digital biomarkers, devices and AI-driven drug discovery.
Therapeutic areas
Oncology, neuroscience, immunology and inflammation, regenerative medicine, rare diseases and infectious diseases
Modalities
Small molecules, biologics, cell and gene therapies, drug delivery, digital biomarkers, devices and AI-driven drug discovery.
Latest Sage news
Latest Sage news
Testimonials
Our experience of working with the partners at Sage in US and Europe has been five star. Their global networks and professionalism in all aspects of our pharma licensing transaction have been key to achieving a 9-figure deal for our company, which was game changing in all respects. I would readily engage with them again, without any hesitation.
Pharma company CEO, 2025
Our experience of working with the partners at Sage in US and Europe has been five star. Their global networks and professionalism in all aspects of our pharma licensing transaction have been key to achieving a 9-figure deal for our company, which was game changing in all respects. I would readily engage with them again, without any hesitation.
Pharma company CEO, 2025
Partnering with Sage was a pivotal move for our organisation. Their strategic insight and global network opened doors to partners we simply could not access on our own. Their team worked as true extensions of ours — deeply commercial, highly responsive, and relentlessly focused on outcomes. We achieved terms that exceeded our expectations and set our programme up for long-term success.
Senior Business Development Executive, Mid-Sized Pharma
Partnering with Sage was a pivotal move for our organisation. Their strategic insight and global network opened doors to partners we simply could not access on our own. Their team worked as true extensions of ours — deeply commercial, highly responsive, and relentlessly focused on outcomes. We achieved terms that exceeded our expectations and set our programme up for long-term success.
Senior Business Development Executive, Mid-Sized Pharma
Sage’s blend of deep sector expertise and practical deal execution was instrumental in closing our licensing agreement. They understood the science and the market, but equally important, they understood people — navigating complex negotiations with professionalism and integrity. I would engage them again without hesitation.
VP, Global Licensing, Biotech
Sage’s blend of deep sector expertise and practical deal execution was instrumental in closing our licensing agreement. They understood the science and the market, but equally important, they understood people — navigating complex negotiations with professionalism and integrity. I would engage them again without hesitation.
VP, Global Licensing, Biotech
In every phase of our transaction, from partner identification to term sheet negotiation, Sage delivered clarity and confidence. Their ability to craft compelling value narratives — rooted in deep industry knowledge — was invaluable in attracting interest from tier-one global partners.
Head of Corporate Development, Global Pharmaceutical Company
In every phase of our transaction, from partner identification to term sheet negotiation, Sage delivered clarity and confidence. Their ability to craft compelling value narratives — rooted in deep industry knowledge — was invaluable in attracting interest from tier-one global partners.
Head of Corporate Development, Global Pharmaceutical Company
We were impressed by Sage’s commitment to tailored strategy and execution. Unlike many advisors who take a templated approach, their team took time to understand our asset, our corporate goals and our risk profile. The end result was a transformative deal that aligned perfectly with our strategic priorities.
Chief Strategy Officer, Emerging Biopharma
We were impressed by Sage’s commitment to tailored strategy and execution. Unlike many advisors who take a templated approach, their team took time to understand our asset, our corporate goals and our risk profile. The end result was a transformative deal that aligned perfectly with our strategic priorities.
Chief Strategy Officer, Emerging Biopharma
Sage brought a level of professionalism and market intelligence that materially elevated our partnering outcomes. Their global reach and relationships were evident throughout the process, and their guidance helped us navigate complex deal terms with confidence.
Executive Director, Licensing & Alliances, Specialty Pharma
Sage brought a level of professionalism and market intelligence that materially elevated our partnering outcomes. Their global reach and relationships were evident throughout the process, and their guidance helped us navigate complex deal terms with confidence.
Executive Director, Licensing & Alliances, Specialty Pharma
© 2026 Sage Healthcare. All rights reserved.
UK Co. Reg No. 03118026
© 2026 Sage Healthcare. All rights reserved.
UK Co. Reg No. 03118026
© 2026. All rights reserved.